WASHINGTON — Immune cells engineered to hunt and destroy cancer cells may help some people with acute lymphoblastic leukemia (ALL) live much longer.
Outcomes depended upon disease severity before treatment, oncologist Jae Park reported April 3 at the American Association for Cancer Research annual meeting.
In ALL — expected to strike 5,970 people and kill 1,440 in the United States in 2017 — immune cells called B cells grow out of control in bone marrow and can spread to other tissues. Overall, five-year survival rates are 71 percent. But fewer than 10…
The post Engineered immune cells boost leukemia survival for some appeared first on FeedBox.